GCI Virtual Summit Thought Leader – Professor Roger Pertwee, University of Aberdeen
Roger participated as a thought leader at the GCI Virtual Summit 2020, joining 1000+ registered global leaders in both cannabis and psychedelics.
Check out his bio below:
Roger Pertwee has three degrees from the University of Oxford: MA (in biochemistry), D.Phil. (in pharmacology) and D.Sc. (in physiological sciences). He is an Emeritus Professor at the University of Aberdeen, where he is still actively engaged in scientific cannabinoid research. He is also co-chairman of the International Union of Basic and Clinical Pharmacology (IUPHAR) Subcommittee on Cannabinoid Receptors, has served twice as President of the International Cannabinoid Research Society (ICRS; 1997-1998 and 2007-2008), and once as chairman of the International Association for Cannabinoid Medicines (IACM; 2005-2007), and is currently serving as International Secretary of the ICRS and as a member of the IACM Board of Directors.
Roger Pertwee received the 2002 Mechoulam Award “for his outstanding contributions to cannabinoid research”, the British Pharmacological Society (BPS) 2011 Wellcome Gold Medal “for outstanding contributions to pharmacology, based mainly on research achievements”, the 2013 IACM Special Award “for his major contributions to the re-introduction of cannabis as a medicine”, the 2018 Lifetime Achievement Award from the ICRS “for outstanding contributions to cannabinoid research and to the ICRS”, and Highly Cited Researcher Awards from Thomson Reuters in 2014 “in recognition of ranking among the top 1% of researchers for most cited documents in their specific field”, and from Clarivate Analytics in 2018 and 2019 “in recognition of exceptional research performance demonstrated by production of multiple highly cited papers, those that rank in the top 1% by citations for field and year in Pharmacology and Toxicology”. He is also an Honorary Fellow of the BPS.
His research has focused mainly on the pharmacology and therapeutic potential of cannabinoids. This cannabinoid research began in 1968 at Oxford University and continued when he moved to Aberdeen University in 1974. His achievements include the joint discovery both of delta-9-tetrahydrocannabivarin in cannabis, and of endocannabinoids (anandamide and 2-arachidonoylglycerol), the discovery of a CB1 receptor allosteric site, and significant contributions to the pharmacological characterization both of phytocannabinoids (e.g. delta-9-tetrahydrocannabivarin, cannabidiol, cannabidiolic acid and cannabigerol) and of notable synthetic cannabinoids (e.g. methanandamide, ACEA, ACPA, AM251, AM281, AM630, HU-308, HU-580, O-1057 and Org27569).
If you are a leader operating in either the cannabis or psychedelics industries, check out the GCI Virtual Summit today! You can submit an application for a complimentary ticket for our 2021 Summit here.
You can also check out exclusive interviews with some of our GCI Virtual Summit thought leaders on the Content Hub.